Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate
2007

Study of Fluticasone Furoate's Binding to Lung Receptors

publication Evidence: high

Author Information

Author(s): Valotis Anagnostis, Högger Petra

Primary Institution: Universität Würzburg, Institut für Pharmazie und Lebensmittelchemie, Würzburg, Germany

Hypothesis

The study aims to characterize the binding affinity of fluticasone furoate to the human lung glucocorticoid receptor compared to other glucocorticoids.

Conclusion

Fluticasone furoate exhibits the highest receptor affinity among currently used glucocorticoids, which may enhance its efficacy in treating respiratory disorders.

Supporting Evidence

  • Fluticasone furoate has a relative receptor affinity of 2989 ± 135, significantly higher than other glucocorticoids.
  • The study found no instability or chemical modification of fluticasone furoate in human lung tissue.
  • Fluticasone furoate showed pronounced retention in human lung tissue compared to other glucocorticoids.

Takeaway

Fluticasone furoate is a new medicine that sticks really well to lung receptors, making it potentially very effective for treating lung problems.

Methodology

The study involved receptor binding experiments using human lung tissue to measure the binding affinity and kinetics of fluticasone furoate compared to other glucocorticoids.

Limitations

The limited sample size may affect the generalizability of the results.

Participant Demographics

Human lung tissue was obtained from patients with bronchial carcinomas who provided informed consent.

Statistical Information

P-Value

p ≤ 0.001

Statistical Significance

p ≤ 0.001

Digital Object Identifier (DOI)

10.1186/1465-9921-8-54

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication